Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.86)
# 1,863
Out of 5,044 analysts
45
Total ratings
38.24%
Success rate
55.35%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $12.93 | +16.01% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.24 | +748.21% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $13.48 | +122.55% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.30 | +1,592.31% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $9.55 | +151.31% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $22.73 | +449.93% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $4.81 | +274.22% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.49 | +444.41% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.33 | - | 1 | Oct 1, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $217.16 | -63.54% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $62.74 | +147.05% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.38 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $9.53 | +162.33% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $5.75 | +31,204.35% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $34.88 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.01 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.78 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $3.35 | +44,676.12% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.82 | +49,350.55% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.38 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $12.50 | +1,220.00% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $104.68 | +114.94% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.91 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.42 | - | 2 | Jan 4, 2017 |
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $12.93
Upside: +16.01%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.24
Upside: +748.21%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.48
Upside: +122.55%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.30
Upside: +1,592.31%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $9.55
Upside: +151.31%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $22.73
Upside: +449.93%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $4.81
Upside: +274.22%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.49
Upside: +444.41%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.33
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $217.16
Upside: -63.54%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $62.74
Upside: +147.05%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $9.38
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $9.53
Upside: +162.33%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $5.75
Upside: +31,204.35%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $34.88
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.01
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.78
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $3.35
Upside: +44,676.12%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.82
Upside: +49,350.55%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.38
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $12.50
Upside: +1,220.00%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $104.68
Upside: +114.94%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $7.91
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.42
Upside: -